Amgen's Vectibix nabs new use in Europe; Mylan launches first generic of Warner Chilcott contraceptive;

@FiercePharma: Medtronic settles DoJ charges for $4.1M on spinal device sales in Malaysia, China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Layoffs for manufacturing units at Amgen, Novartis contributed to sizable cuts last year. Check out the new feature | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals. Report | Follow @CarlyHFierce

> Amgen's ($AMGN) colon cancer drug Vectibix won broader approval in Europe, as a first-line treatment in certain patients, in combination with a chemotherapy regimen called FOLFIRI. Report

> Mylan ($MYL) rolled out its version of Generess Fe, a contraceptive brand marketed by Warner Chilcott; it's the first generic form of the product. Report

> AbbVie ($ABBV) asked a U.S. judge to dismiss claims by Shire ($SHPG) shareholders, who say the Illinois-based company misrepresented the importance of tax incentives in its aborted agreement to buy Shire. Report

> A U.S. judge tossed out one the few remaining thalidomide cases against GlaxoSmithKline ($GSK), Legal Intelligencer reports. Article

> Roche's ($RHHBY) Rituxan, approved to treat blood cancers and rheumatoid arthritis, could be a treatment option for a rare disease known as eosinophilic granulomatosis and polyangiitis (EGPA), a study found. Report

Medical Device News

@FierceMedDev: Check out the top med tech companies of 2014. Feature | Follow @FierceMedDev

@VarunSaxena2: Experts: Stent retrieval devices to play larger role in treatment of stroke. Story | Follow @VarunSaxena2

@EmilyWFierce: Natera ropes in $55M with eye on cancer Dx. FierceDiagnostics article | Follow @EmilyWFierce

> Miniaturized skin cancer device emerges as alternative to surgery. Article

> J&J's Ethicon gets FDA clearance to use Evarrest patch for liver surgery. Report

Biotech News

@FierceBiotech: High-flying immuno-oncology player Adaptimmune pitches $150M IPO. News | Follow @FierceBiotech

@JohnCFierce: Plotting a course for True North, biotech CEO steps up with a $35M round. Report | Follow @JohnCFierce

> CRISPR-Cas9 pioneer starts recruiting R&D group in Cambridge hub. More

> Merck wagers $434M on Arvinas and its protein-disposal system. Report

> Ocular Therapeutix plunges as eye treatment blurs the line in PhIII. Article

> Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. News

Drug Delivery News

> Gold nanoparticles deliver RNA to the brain to suppress cancer genes. Story

> Developer of Botox lotion files for $58M IPO. Item

> Researchers take aim at childhood neuroblastoma with targeted nanoparticles. More

> Actavis' drug delivery-focused spinoff on the prowl for acquisitions. Report

> AstraZeneca gets FDA nod for alternative administration of oral heart med. Article

Pharma Manufacturing News

> AMRI moves forward with plan to close Wales API plant, cut 62 jobs. Item

> Baxter recalls more than half a million units of saline. News

> North Carolina compounder is closed and its products are recalled. Story

> India's Mankind Pharma investing $16M in API plant. Article

> UAE drug distributor building a $20M plant in Dubai. Report

Pharma Asia News

> Australia-China researchers eye Asian stroke drug for Alzheimer's disease. Story

> South Korea struggles with healthcare needs of elderly. Report

> Second quarter pharma market outlooks for pan-Asia mixed, India promising. Story

> India's Mankind sees 15th product plant online this year. Article

> Sirtex Medical oncology play still has some thunder Down Under. More

And Finally... The "Baron of Botox," dermatologist Dr. Fredric Brandt, died Sunday at his Florida home; police say he committed suicide. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.